Neil French1, Stephen B Gordon2, Thandie Mwalukomo3, Sarah A White4, Gershom Mwafulirwa4, Herbert Longwe4, Martin Mwaiponya3, Eduard E Zijlstra3, Malcolm E Molyneux2, Charles F Gilks5. 1. Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi; Karonga Prevention Study, London School of Hygiene and Tropical Medicine, Karonga, Malawi. 2. Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi; Liverpool School of Tropical Medicine, Liverpool, United Kingdom. 3. Department of Medicine, College of Medicine, University of Malawi, Blantyre, Malawi. 4. Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi. 5. Imperial College London, London, United Kingdom.
Abstract
BACKGROUND: Streptococcus pneumoniae is a leading and serious coinfection in adults with human immunodeficiency virus (HIV) infection, particularly in Africa. Prevention of this disease by vaccination with the current 23-valent polysaccharide vaccine is suboptimal. Protein conjugate vaccines offer a further option for protection, but data on their clinical efficacy in adults are needed. METHODS: In this double-blind, randomized, placebo-controlled clinical efficacy trial, we studied the efficacy of a 7-valent conjugate pneumococcal vaccine in predominantly HIV-infected Malawian adolescents and adults who had recovered from documented invasive pneumococcal disease. Two doses of vaccine were given 4 weeks apart. The primary end point was a further episode of pneumococcal infection caused by vaccine serotypes or serotype 6A. RESULTS: From February 2003 through October 2007, we followed 496 patients (of whom 44% were male and 88% were HIV-seropositive) for 798 person-years of observation. There were 67 episodes of pneumococcal disease in 52 patients, all in the HIV-infected subgroup. In 24 patients, there were 19 episodes that were caused by vaccine serotypes and 5 episodes that were caused by the 6A serotype. Of these episodes, 5 occurred in the vaccine group and 19 in the placebo group, for a vaccine efficacy of 74% (95% confidence interval [CI], 30 to 90). There were 73 deaths from any cause in the vaccine group and 63 in the placebo group (hazard ratio in the vaccine group, 1.18; 95% CI, 0.84 to 1.66). The number of serious adverse events within 14 days after vaccination was significantly lower in the vaccine group than in the placebo group (3 vs. 17, P = 0.002), and the number of minor adverse events was significantly higher in the vaccine group (41 vs. 13, P = 0.003). CONCLUSIONS: The 7-valent pneumococcal conjugate vaccine protected HIV-infected adults from recurrent pneumococcal infection caused by vaccine serotypes or serotype 6A. (Current Controlled Trials number, ISRCTN54494731.).
RCT Entities:
BACKGROUND:Streptococcus pneumoniae is a leading and serious coinfection in adults with human immunodeficiency virus (HIV) infection, particularly in Africa. Prevention of this disease by vaccination with the current 23-valent polysaccharide vaccine is suboptimal. Protein conjugate vaccines offer a further option for protection, but data on their clinical efficacy in adults are needed. METHODS: In this double-blind, randomized, placebo-controlled clinical efficacy trial, we studied the efficacy of a 7-valent conjugate pneumococcal vaccine in predominantly HIV-infected Malawian adolescents and adults who had recovered from documented invasive pneumococcal disease. Two doses of vaccine were given 4 weeks apart. The primary end point was a further episode of pneumococcal infection caused by vaccine serotypes or serotype 6A. RESULTS: From February 2003 through October 2007, we followed 496 patients (of whom 44% were male and 88% were HIV-seropositive) for 798 person-years of observation. There were 67 episodes of pneumococcal disease in 52 patients, all in the HIV-infected subgroup. In 24 patients, there were 19 episodes that were caused by vaccine serotypes and 5 episodes that were caused by the 6A serotype. Of these episodes, 5 occurred in the vaccine group and 19 in the placebo group, for a vaccine efficacy of 74% (95% confidence interval [CI], 30 to 90). There were 73 deaths from any cause in the vaccine group and 63 in the placebo group (hazard ratio in the vaccine group, 1.18; 95% CI, 0.84 to 1.66). The number of serious adverse events within 14 days after vaccination was significantly lower in the vaccine group than in the placebo group (3 vs. 17, P = 0.002), and the number of minor adverse events was significantly higher in the vaccine group (41 vs. 13, P = 0.003). CONCLUSIONS: The 7-valent pneumococcal conjugate vaccine protected HIV-infected adults from recurrent pneumococcal infection caused by vaccine serotypes or serotype 6A. (Current Controlled Trials number, ISRCTN54494731.).
Authors: Joseph Kwong-Leung Yu; Solomon Chih-Cheng Chen; Kuo-Yang Wang; Chao-Sung Chang; Simon D Makombe; Erik J Schouten; Anthony D Harries Journal: Bull World Health Organ Date: 2007-07 Impact factor: 9.408
Authors: Imma Grau; Roman Pallares; Fe Tubau; Marco H Schulze; Ferran Llopis; Daniel Podzamczer; Josefina Liñares; Francesc Gudiol Journal: Arch Intern Med Date: 2005-07-11
Authors: Cynthia G Whitney; Monica M Farley; James Hadler; Lee H Harrison; Nancy M Bennett; Ruth Lynfield; Arthur Reingold; Paul R Cieslak; Tamara Pilishvili; Delois Jackson; Richard R Facklam; James H Jorgensen; Anne Schuchat Journal: N Engl J Med Date: 2003-05-01 Impact factor: 91.245
Authors: Matthew Scarborough; Stephen B Gordon; Christopher J M Whitty; Neil French; Yasin Njalale; Alex Chitani; Timothy E A Peto; David G Lalloo; Eduard E Zijlstra Journal: N Engl J Med Date: 2007-12-13 Impact factor: 91.245
Authors: C F Gilks; S A Ojoo; J C Ojoo; R J Brindle; J Paul; B I Batchelor; J N Kimari; R Newnham; J Bwayo; F A Plummer Journal: Lancet Date: 1996-03-16 Impact factor: 79.321
Authors: Keith P Klugman; Shabir A Madhi; Robin E Huebner; Robert Kohberger; Nontombi Mbelle; Nathaniel Pierce Journal: N Engl J Med Date: 2003-10-02 Impact factor: 91.245
Authors: Stephen B Gordon; Stonard Kanyanda; Amanda L Walsh; Kirsty Goddard; Mas Chaponda; Victoria Atkinson; Wakisa Mulwafu; Elizabeth M Molyneux; Ed E Zijlstra; Malcolm E Molyneux; Steve M Graham Journal: Emerg Infect Dis Date: 2003-06 Impact factor: 6.883